(Alliance News) - Shield Therapeutics PLC on Thursday said Chair James Karis acquired shares in the pharmaceutical company following a transaction on Tuesday.Karis purchased 75,000 shares a Read More
(Alliance News) - Drugmaker Shield Therapeutics said on Wednesday a payment from a commercial partner contributed to a sharp revenue rise in the first half of the year.In the six months to Read More
LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd has filed a notice of appeal on a decision regarding a Shield in a Read More
LONDON (Alliance News) - Shield Therapeutics PLC said on Friday that Chief Medical Officer Mark Sampson and his wife Julia have purchased shares in the company on Thursday.Mark bought at a Read More
LONDON (Alliance News) - Shield Therapeutics PLC said on Wednesday said the Swiss Agency for Therapeutic Products has approved the Feraccru product to treat iron deficiency in adults with or is to Read More
LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at Read More
LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at Read More
LONDON (Alliance News) - Drug maker Shield Therapeutics PLC said Wednesday its 2018 loss narrowed significantly as revenue surged on a licence payment boost amid a year of "transition" a Read More
LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said its Feraccru patent met the requirements of the European Patent Convention, which will continue to provide protection to Feraccru Read More
LONDON (Alliance News) - Shield Therapeutics PLC on Tuesday reported positive results from a long-term study of its lead treatment for iron deficiency, Ferracru.Shares in the company were a Read More
LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said it expects its revenue to surge in 2018 on the back of licence payments for its Feraccru capsules.The pharmaceutical has in Read More
LONDON (Alliance News) - Shield Therapeutics PLC said Tuesday that it has promoted board member James Karis to be non-executive chair with immediate effect.Karis has served on Shield's Read More
LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday that Norgine BV has launched the company's treatment for iron deficiency, Ferracru, in the UK.In September 2018, Shield, Read More
LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Chief Executive Carl Sterritt bought more shares in the company in a deal on Friday last week.Sterritt pruchased 88,235 at 34 Read More
LONDON (Alliance News) - Shield Therapeutics PLC said on Thursday it has completed recruitment of patients for the AEGIS-H2H Phase 3b study of oral Feraccru in subjects suffering from inflammatory Read More
LONDON (Alliance News) - Shield Therapeutics PLC, a commercial stage pharmaceutical company, said Thursday that it has appointed Hans-Peter Hasler as non-executive director with immediate is the a Read More
LONDON (Alliance News) - Pharmaceutical company Shield Therapeutics PLC said Thursday it has had positive top-line results from its paediatric phase I pharmacokinetics study of its ferric iron is Read More
